Urethritis Diagnosis: A Comprehensive Guide for Clinicians

Introduction

Urethritis, an inflammation of the urethra, is a common lower urinary tract condition affecting both males and females. This fibromuscular tube plays a crucial role in expelling urine and, in males, semen. Predominantly linked to sexually transmitted infections (STIs), urethritis is broadly categorized into gonococcal and nongonococcal types, with Neisseria gonorrhoeae and Chlamydia trachomatis being the primary culprits. Urethral discharge is a hallmark symptom, prompting patients to seek medical attention. Accurate Urethritis Diagnosis is paramount not only for effective patient management but also for curbing the spread of STIs within communities.

The diagnostic process for urethritis is multifaceted, beginning with a detailed patient history and physical examination. Laboratory investigations are indispensable to confirm infection and pinpoint the causative pathogen. While spontaneous symptom resolution can occur, antibiotic therapy is generally recommended, particularly when infection is confirmed or for sexual partners of infected individuals. This comprehensive guide delves into the essential aspects of urethritis diagnosis, evaluation, and management, emphasizing the collaborative role of interprofessional healthcare teams in optimizing patient outcomes and public health. Effective collaboration ensures well-coordinated care, enhancing patient outcomes and contributing to the broader effort of STI prevention and control.

Etiology of Urethritis

Urethritis is primarily caused by infectious agents, with STIs leading the list. However, non-infectious causes also contribute to urethral inflammation. Understanding the diverse etiologies is crucial for accurate urethritis diagnosis and targeted treatment.

Sexually Transmitted Urethritis

Sexually transmitted urethritis is classified into two main categories:

• Gonococcal Urethritis: Caused by Neisseria gonorrhoeae, this type represents a significant portion of STI-related urethritis cases. N gonorrhoeae is a gram-negative diplococcus transmitted through sexual contact, with an incubation period ranging from 2 to 5 days. Co-infection with Chlamydia trachomatis is frequently observed, highlighting the importance of broad-spectrum testing in urethritis diagnosis. Gonorrhea can also negatively impact semen parameters and contribute to male infertility.

• Nongonococcal Urethritis (NGU): This category encompasses urethritis caused by pathogens other than N gonorrhoeae. The most common culprits include Chlamydia trachomatis and Mycoplasma genitalium.

  • Chlamydia trachomatis: The leading cause of NGU, C trachomatis, is a gram-negative intracellular bacterium transmitted sexually. Its incubation period is typically longer, ranging from 7 to 14 days. Chlamydial urethritis is often asymptomatic, making urethritis diagnosis challenging but crucial for preventing complications and onward transmission. It is also frequently associated with M genitalium and N gonorrhoeae. Furthermore, C trachomatis infections have been linked to male infertility and compromised semen quality.

  • Mycoplasma genitalium: This organism is a significant cause of persistent or recurrent urethritis, particularly in men with NGU who test negative for chlamydia. M genitalium is a small bacterium lacking a cell wall, making it difficult to detect via traditional Gram staining and culture methods. Its slow-growing nature further complicates urethritis diagnosis, with cultures often yielding low positivity rates.

  • Other Infectious Agents: Beyond the primary pathogens, other infectious agents can cause urethritis:

    • Candida spp.: These fungal yeasts can cause urogenital infections and irritation, contributing to urethritis symptoms.
    • Haemophilus influenzae: While less common, H influenzae can cause urethritis, often transmitted through oral sex.
    • Treponema pallidum: Syphilitic chancres, though rare, can occur in the urethra, leading to urethritis.
    • Ureaplasma urealyticum and Ureaplasma parvum: These bacteria are less frequently associated with urethritis but can be causative agents, especially in younger men or those with fewer sexual partners, when other NGU etiologies are ruled out during urethritis diagnosis.
    • Trichomonas vaginalis: This protozoan parasite is a recognized cause of urethritis, particularly in men, and should be considered in differential urethritis diagnosis.
    • Adenoviruses: Certain viral infections, like adenovirus, can also manifest as urethritis, often presenting with distinct symptoms like intense dysuria.

Non-Infectious Urethritis Etiologies

While infections are the predominant cause, non-infectious factors can also trigger urethritis:

• Irritation: Chemical or physical irritants can inflame the urethra.

  • Tight clothing, sexual activity, and certain physical exercises (like cycling or horseback riding) can cause friction and irritation.
  • Soaps, douches, spermicides, and body powders can introduce chemical irritants.

• Trauma: Direct injury to the urethra can lead to inflammation.

  • Urethral instrumentation, intermittent catheterization, or insertion of foreign bodies can cause traumatic urethritis.

• Estrogen Deficiency: In postmenopausal women, reduced estrogen levels can lead to atrophic vaginitis and urethritis due to thinning and drying of urethral and bladder tissues. This is a significant cause of urethritis in older women and should be considered in urethritis diagnosis for this demographic.

Epidemiology of Urethritis

Urethritis is a significant public health concern due to its high incidence and association with STIs. Understanding the epidemiology is vital for targeted prevention and effective urethritis diagnosis strategies.

In the United States, approximately 4 million individuals are affected by urethritis annually. Gonococcal urethritis accounts for over 600,000 new cases each year, while nongonococcal urethritis is responsible for about 3 million new cases. Globally, the burden is even greater, with an estimated 62 million new cases of gonococcal urethritis and 89 million new cases of nongonococcal urethritis each year.

Studies examining men with acute urethritis symptoms reveal that N gonorrhoeae is identified in around 30% of cases. Among the remaining NGU cases, C trachomatis accounts for nearly half. In non-chlamydial NGU, M genitalium, Ureaplasma species, adenoviruses, Haemophilus influenzae, HSV, Mycoplasma hominis, Neisseria meningitidis, and Trichomonas vaginalis are identified as causative agents, albeit in varying proportions.

Urethritis is more frequently diagnosed in males. This disparity may be attributed to the higher likelihood of women being asymptomatic (up to 75%) or presenting with symptoms of related conditions like cervicitis, cystitis, or vaginitis, which may overshadow urethritis in initial urethritis diagnosis.

Risk factors for urethritis are strongly linked to sexual activity and STI acquisition:

• Young Age: Individuals aged 20 to 24 are most commonly affected, reflecting higher rates of sexual activity in this age group.
• Unprotected Sexual Intercourse: Lack of barrier methods increases the risk of STI transmission and subsequent urethritis.
• Multiple Sexual Partners: Having multiple partners elevates the risk of exposure to STIs.
• Men Who Have Sex with Men (MSM): This population has a higher prevalence of STIs, including urethritis.
• History of STIs: Previous STI diagnosis increases the risk of future infections, including urethritis.

Chlamydia trachomatis, a leading cause of NGU, is also one of the most prevalent STIs globally. It primarily infects the columnar epithelium of the urethral mucosa, leading to cellular damage during replication. Understanding these epidemiological patterns informs public health strategies and enhances clinical vigilance in urethritis diagnosis among at-risk populations.

Pathophysiology of Urethritis

The pathophysiology of urethritis involves inflammatory responses within the urethral mucosa, triggered by infectious or non-infectious agents. These inflammatory processes are key to urethritis diagnosis and understanding symptom manifestation.

Infectious Urethritis:

• Bacterial Adherence and Invasion: Pathogenic bacteria, such as N gonorrhoeae and C trachomatis, adhere to and invade the urethral epithelium. N gonorrhoeae utilizes pili to attach to mucosal cells, while C trachomatis enters cells via endocytosis.
• Inflammatory Cascade: The presence of these pathogens triggers an immune response. Host cells release cytokines and chemokines, attracting neutrophils and other inflammatory cells to the site of infection.
• Urethral Damage: Inflammation leads to urethral mucosa edema, hyperemia, and cellular damage. In gonococcal urethritis, there is often a more pronounced purulent discharge due to the intense neutrophilic infiltration. Chlamydia infection induces a more lymphocytic response, which may contribute to the often milder and mucopurulent discharge seen in NGU.
• Urethral Discharge Formation: The characteristic urethral discharge in urethritis is a result of the inflammatory exudate, composed of neutrophils, cellular debris, and pathogen material.

Non-Infectious Urethritis:

• Irritation and Trauma: Mechanical or chemical irritation causes direct damage to the urethral mucosa. This damage leads to the release of inflammatory mediators, resulting in localized inflammation, albeit typically less intense than in infectious urethritis.
• Estrogen Deficiency: In atrophic urethritis, estrogen deficiency leads to thinning and reduced vascularity of the urethral epithelium, making it more susceptible to irritation and inflammation.

Diagnostic Markers:

• White Blood Cells (WBCs): The presence of increased WBCs in urethral secretions or first-void urine is a hallmark of urethritis. A Gram stain showing ≥2 WBCs per oil immersion field or a first-void urine sample with ≥10 WBCs per high-power field are diagnostic criteria.
• Leukocyte Esterase: This enzyme, released by neutrophils, can be detected in urine and serves as an indicator of inflammation in the urinary tract, supporting urethritis diagnosis.
• Nucleic Acid Amplification Tests (NAATs): These highly sensitive tests detect pathogen-specific DNA or RNA in urethral samples or urine, providing definitive urethritis diagnosis and identification of causative agents like N gonorrhoeae, C trachomatis, and M genitalium.

Untreated urethritis in men can lead to complications like infertility, while in women, it can progress to pelvic inflammatory disease (PID) in a significant proportion of cases, even when initially asymptomatic. Understanding the pathophysiology underscores the importance of early urethritis diagnosis and treatment to prevent sequelae and transmission.

Histopathology in Urethritis Diagnosis

Histopathological examination of urethral discharge can provide valuable insights for urethritis diagnosis, particularly in differentiating between gonococcal and nongonococcal urethritis.

Gonococcal Urethritis:

• Microscopic Findings: Gram staining of urethral discharge typically reveals gram-negative intracellular diplococci within neutrophils. These diplococci are characteristic of Neisseria gonorrhoeae, providing rapid presumptive urethritis diagnosis. The presence of intracellular diplococci is a strong indicator of gonococcal infection.

Nongonococcal Urethritis (NGU):

• Microscopic Findings: In NGU, Gram staining will show leukocytes (WBCs) but without the presence of gram-negative intracellular diplococci. This absence is a key differentiator from gonococcal urethritis.
• Chlamydia trachomatis: While C trachomatis is an intracellular bacterium, it lacks peptidoglycans in its cell wall, preventing it from taking up Gram stain effectively. Therefore, Gram stain alone cannot definitively identify Chlamydia as the cause of NGU. Other diagnostic methods like NAAT are necessary for specific urethritis diagnosis in NGU.

Limitations of Histopathology:

• Sensitivity: Gram stain sensitivity for gonococcal urethritis is high, but it is less helpful in NGU, where multiple pathogens can be involved, and Gram stain does not identify them specifically.
• NGU Etiology: Histopathology cannot pinpoint the specific pathogen in NGU. Further testing, such as NAAT, is essential to identify C trachomatis, M genitalium, Trichomonas vaginalis, or other NGU causative agents for targeted urethritis diagnosis and treatment.

In summary, while histopathology via Gram stain is a rapid and useful initial step in urethritis diagnosis, particularly for gonococcal infection, it is often complemented by more specific laboratory tests like NAATs to achieve accurate and comprehensive pathogen identification, especially in cases of nongonococcal urethritis.

History and Physical Examination in Urethritis Diagnosis

A thorough history and physical examination are foundational to urethritis diagnosis. These steps help clinicians assess risk factors, symptom presentation, and guide appropriate laboratory testing.

History Taking

• Symptom Assessment:

  • Urethral Discharge: Inquire about the presence, onset, color, consistency, and quantity of discharge. Purulent discharge suggests gonorrhea, while clear or whitish discharge may indicate chlamydia. However, discharge characteristics are not definitively diagnostic and laboratory confirmation is needed for accurate urethritis diagnosis.
  • Dysuria: Assess the presence, severity, location (meatus or distal penis), and timing of dysuria (worse in the morning, after alcohol). Dysuria alone is more common in chlamydial infections, while severe dysuria with genital ulcers suggests HSV.
  • Pruritus and Burning: Ask about urethral itching or stinging, which may occur between voiding.
  • Orchalgia: Inquire about testicular pain, which can be associated with urethritis complications.
  • Voiding Symptoms: Assess for urinary frequency and urgency, though these are less typical in uncomplicated urethritis unless cystitis or other conditions are present.
  • Systemic Symptoms: Note the absence or presence of systemic symptoms like fever, chills, or malaise, which are generally not prominent in urethritis.
  • Menstrual Cycle Variation (in women): Ask if symptoms worsen during menstruation, which can occur in some women.

• Sexual History: This is crucial for risk stratification and guiding urethritis diagnosis.

  • Sexual Activity: Inquire about recent sexual activity, including type of contact (vaginal, anal, oral), number of partners, and condom use.
  • Partner Symptoms: Ask if sexual partners have symptoms of STIs or have been diagnosed with urethritis or STIs.
  • History of STIs: Document any previous STI diagnoses in the patient.
  • Specific Risk Factors: Identify risk factors such as young age, multiple partners, unprotected sex, MSM status, and commercial sex work.

• Medical History:

  • Allergies: Document any allergies, especially to antibiotics, as this will influence treatment choices.
  • Medications: Record current medications, including over-the-counter drugs and supplements.
  • Pregnancy Status (in women): Determine if the patient is pregnant or breastfeeding, as this affects treatment options.
  • Menopausal Status (in women): Consider menopausal status in women presenting with urethritis symptoms, as estrogen deficiency can be a contributing factor.

• Specific Etiology Clues:

  • Adenovirus: Consider adenovirus if intense dysuria is reported without significant discharge, especially during fall/winter months and with a history of oral sex and upper respiratory symptoms.
  • C. glucuronolyticum: Suspect this in post-chlamydia treatment urethritis, characterized by dysuria and minimal clear discharge.
  • HSV: Consider HSV if painful genital ulcers are present with dysuria.

Physical Examination

• General Examination: Assess for systemic signs, although these are typically absent in urethritis.

• Genitourinary Examination (Males):

  • Inspection: Examine underwear for discharge stains. Inspect penis and external genitalia for lesions, rashes, or signs of STIs. Retract foreskin in uncircumcised men to check for lesions, meatitis, and discharge.
  • Palpation: Palpate abdomen for suprapubic tenderness. Palpate the urethra along the penile shaft for abscesses or foreign bodies. Perform bilateral testicular examination for tenderness or swelling (epididymitis, orchitis). Check for inguinal lymphadenopathy. Digital rectal exam of the prostate if indicated.
  • Urethral Meatus: Assess for redness, swelling (meatitis), and discharge.
  • Discharge Collection: If discharge is not readily apparent, gently “milk” the penis to express urethral secretions for Gram stain and other tests. Ideally, the patient should not have voided for at least 2 hours prior to examination to maximize discharge detection. Collect first-void urine sample.

• Pelvic Examination (Females): Position patient in lithotomy or frog-leg position.

  • External Genitalia: Inspect for lesions, discharge, or signs of STIs.
  • Urethral Examination: Examine urethra for inflammation, discharge, and tenderness.
  • Pelvic Exam: Conduct a full pelvic examination, including urethra, anterior vaginal wall, cervix, and adnexa to assess for cervicitis, vaginitis, or PID.
  • Urethral Stripping: Perform urethral stripping to express discharge for testing if needed.

By combining a detailed patient history with a focused physical examination, clinicians can effectively narrow the differential diagnosis, identify risk factors, and determine the necessary laboratory tests to confirm urethritis diagnosis and guide appropriate management.

Evaluation and Diagnostic Testing for Urethritis

Urethritis diagnosis relies on a combination of clinical findings and laboratory tests. Evaluation begins with recognizing clinical indicators, followed by specific diagnostic procedures to confirm the diagnosis and identify the causative agent.

Clinical Diagnosis

Urethritis is clinically suspected in sexually active individuals presenting with:

• Urethral Symptoms: Dysuria, urethral pruritus, or urethral discharge.
• Clinical Signs: Mucopurulent or purulent urethral discharge observed during physical examination.

Clinical diagnosis is supported by evidence of urethral inflammation, indicated by:

• Leukocyte Esterase Positive Urine: Positive leukocyte esterase test on first-void urine.
• Elevated White Blood Cells (WBCs) in Urine: Microscopic examination of first-void urine sediment showing ≥10 WBCs per high-power field, in the absence of a urinary tract infection (UTI).

Laboratory Diagnostic Tests

Specific laboratory tests are crucial for confirming urethritis diagnosis and identifying the etiology.

1. Gram Stain of Urethral Discharge:

   • Procedure: Urethral discharge is smeared on a slide and Gram stained.
   • Interpretation:
     • Gonococcal Urethritis: Presence of gram-negative intracellular diplococci within neutrophils is highly suggestive of Neisseria gonorrhoeae infection.
     • Nongonococcal Urethritis: Presence of leukocytes (WBCs) without gram-negative intracellular diplococci indicates NGU.
   • Advantages: Rapid, inexpensive, can differentiate gonococcal from nongonococcal urethritis initially.
   • Limitations: Less sensitive than NAAT, cannot identify specific NGU pathogens, requires adequate discharge sample.

2. Methylene Blue/Gentian Violet (MB/GV) Smear:

   • Procedure: Similar to Gram stain but uses MB/GV stain without heat fixation.
   • Interpretation: Comparable to Gram stain in detecting gonococcal urethritis with high sensitivity and specificity.
   • Advantages: Rapid, simpler than Gram stain, similar diagnostic accuracy for gonococcal urethritis.

3. Nucleic Acid Amplification Tests (NAATs):

   • Procedure: Detect pathogen-specific DNA or RNA in first-void urine, urethral swabs (males), or endocervical swabs (females).
   • Targets: Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium.
   • Advantages: High sensitivity and specificity, preferred method for detecting C trachomatis, N gonorrhoeae, M genitalium, and T vaginalis, can be performed on urine samples (non-invasive).
   • Limitations: More expensive than microscopy, turnaround time may be longer, may not be readily available for all pathogens (e.g., M genitalium testing availability varies).

4. Urine and Urethral Cultures:

   • Procedure: Urine or urethral swabs are cultured to grow and identify bacterial or fungal pathogens.
   • Targets: Neisseria gonorrhoeae, Candida spp., and other bacteria.
   • Advantages: Allows for antimicrobial susceptibility testing, useful for diagnosing N gonorrhoeae and guiding antibiotic choice in resistant cases, can identify less common bacterial causes.
   • Limitations: Less sensitive than NAAT for C trachomatis and M genitalium, M genitalium is difficult to culture, culture turnaround time is longer.

5. Additional Tests:

   • STI Screening: All patients with urethritis should be tested for other STIs, including syphilis (serology: RPR, VDRL) and HIV.
   • Trichomonas vaginalis Testing: NAAT for T vaginalis should be considered, especially in persistent or recurrent urethritis or in high-prevalence areas. Wet mount microscopy can also be used, but is less sensitive than NAAT.
   • Mycoplasma genitalium Testing: NAAT for M genitalium is increasingly important, particularly in persistent or recurrent NGU, or in cases unresponsive to initial treatment. Availability may vary.
   • Fungal Testing: Potassium hydroxide (KOH) preparation of urethral discharge may be used if fungal urethritis (candidiasis) is suspected.
   • Pregnancy Test: As appropriate for women of reproductive age, as pregnancy influences treatment choices.
   • Nasopharyngeal and Rectal Swabs for N gonorrhoeae: Recommended for men who have sex with men or those with a history of oral or anal sex.
   • Urinalysis: While not diagnostic for urethritis itself, urinalysis can help rule out UTI and assess for pyuria (WBCs in urine), supporting the diagnosis of urethritis.

Diagnostic Algorithm:

1. Initial Assessment: Clinical suspicion based on symptoms and risk factors.
2. Microscopy: Gram stain or MB/GV smear for rapid assessment and differentiation of gonococcal urethritis.
3. NAATs: Perform NAAT on first-void urine or swabs for C trachomatis and N gonorrhoeae as standard. Consider NAAT for M genitalium and T vaginalis based on clinical context and availability.
4. Culture: Culture for N gonorrhoeae if antimicrobial resistance is a concern or for susceptibility testing if treatment failure occurs.
5. STI Screening: Screen for other STIs (HIV, syphilis).
6. Further Investigation: If initial tests are negative and symptoms persist, consider testing for less common pathogens (M genitalium, T vaginalis, Haemophilus influenzae, adenovirus), and evaluate for non-infectious causes.

By employing a strategic approach to urethritis diagnosis, combining clinical evaluation with appropriate laboratory testing, clinicians can achieve accurate pathogen identification, guide effective treatment, and contribute to STI control efforts.

Treatment and Management of Urethritis

Treatment of urethritis aims to eradicate infection, alleviate symptoms, and prevent complications and further transmission. Antibiotic therapy is the mainstay of management for infectious urethritis.

General Treatment Principles

• Antibiotic Therapy: Recommended in all confirmed cases of infectious urethritis and empirically in cases of high suspicion, especially when follow-up is uncertain or for sexual partners of infected individuals.
• Empiric Therapy: Often initiated before specific pathogen identification, targeting the most common causative agents (N gonorrhoeae and C trachomatis) with broad-spectrum antibiotics.
• Partner Treatment: Crucial to treat sexual partners to prevent reinfection and further spread of STIs.
• Abstinence: Patients should abstain from sexual intercourse until they and their partners have completed treatment and are symptom-free.
• Test of Cure: Repeat testing is recommended, particularly for N gonorrhoeae and Trichomonas vaginalis, and for Chlamydia trachomatis in pregnant women and in cases of suspected treatment failure. For M. genitalium, test of cure is recommended to assess for treatment success and resistance.
• STI Screening: Patients diagnosed with urethritis should be screened for other STIs (HIV, syphilis).

Recommended Treatment Regimens

The Centers for Disease Control and Prevention (CDC) and other guidelines provide recommendations for urethritis treatment, considering both gonococcal and nongonococcal etiologies.

1. Gonococcal Urethritis:

• Primary Regimen:
  • Ceftriaxone: 500 mg intramuscularly (IM) in a single dose for patients <150 kg body weight. 1 g IM single dose for patients ≥150 kg.
  • If Chlamydia trachomatis is not ruled out: Add doxycycline 100 mg orally twice daily for 7 days.
• Alternative Regimens (if ceftriaxone is unavailable or contraindicated):
  • Gentamicin 240 mg IM single dose PLUS Azithromycin 2 g orally single dose.
  • Cefixime 800 mg orally single dose (less effective than ceftriaxone, not preferred).
• Avoid: Quinolones and oral cephalosporins are not recommended due to high rates of antibiotic resistance in N gonorrhoeae. Azithromycin monotherapy is also not recommended due to increasing resistance.

2. Nongonococcal Urethritis (NGU):

• Empiric Therapy (when specific pathogen is not identified):
  • Doxycycline: 100 mg orally twice daily for 7 days.
  • Alternative: Azithromycin 1 g orally single dose (less preferred due to emerging resistance).
• Chlamydia trachomatis Specific Treatment:
  • Doxycycline: 100 mg orally twice daily for 7 days (preferred).
  • Azithromycin: 1 g orally single dose (alternative, but consider resistance patterns). Multidose azithromycin regimens (e.g., 500 mg day 1, then 250 mg days 2-5) may be considered for improved efficacy.
• Mycoplasma genitalium Treatment:
  • Azithromycin: 1 g orally single dose (initial treatment).
  • If Azithromycin Resistance Suspected or Proven: Moxifloxacin 400 mg orally once daily for 7 days.
  • Alternative Regimens for M genitalium (if moxifloxacin fails or is contraindicated): Doxycycline 100 mg orally twice daily for 7 days followed by moxifloxacin 400 mg orally daily for 7 days; or Pristinamycin (if available, not in the US).
• Trichomonas vaginalis Treatment:
  • Metronidazole: 500 mg orally twice daily for 7 days (women, including pregnant women, preferred).
  • Metronidazole: 2 g orally single dose (men, alternative tinidazole). Partner treatment is essential.

3. Treatment Failure:

• Persistent or Recurrent NGU: Often due to M genitalium or Trichomonas vaginalis or reinfection.
• Management of Doxycycline Failure in NGU: Consider M genitalium and treat with azithromycin or moxifloxacin, guided by resistance testing if available. If T vaginalis is suspected, test and treat with metronidazole.

4. Special Populations:

• Pregnant Women:
  • Chlamydia: Azithromycin 1 g orally single dose is preferred. Alternatives: Amoxicillin, erythromycin (multiple regimens available, see guidelines). Doxycycline and fluoroquinolones are contraindicated in pregnancy.
  • Gonorrhea: Ceftriaxone is safe in pregnancy.
  • Trichomonas: Metronidazole is safe in pregnancy.
• C. glucuronolyticum Urethritis: Treatment guided by culture and sensitivity testing due to antibiotic resistance.
• H. influenzae Urethritis: Treatment guided by culture and sensitivity, considering local resistance patterns.

5. Non-Infectious Urethritis Management:

• Irritant Urethritis: Avoid irritants, change soaps, wear loose clothing, avoid douches and spermicides.
• Traumatic Urethritis: Manage underlying cause, supportive care, avoid further trauma.
• Atrophic Urethritis (postmenopausal women): Topical estrogen therapy may be beneficial.

Effective urethritis diagnosis coupled with appropriate and timely treatment is critical to improve patient outcomes, prevent complications, and control the spread of STIs. Clinicians should stay updated with current treatment guidelines and antibiotic resistance patterns to optimize patient care.

Differential Diagnosis of Urethritis

When evaluating patients with symptoms suggestive of urethritis, it is essential to consider other conditions that can mimic urethritis. A thorough differential urethritis diagnosis is crucial for accurate management.

Conditions to Differentiate from Urethritis:

1. Urinary Tract Infection (UTI) / Cystitis:

   • Overlap: Dysuria, urinary frequency, and urgency can occur in both urethritis and cystitis.
   • Differentiation: Cystitis typically involves more prominent urinary frequency, urgency, suprapubic pain, and hematuria. Urethritis is more characterized by urethral discharge and dysuria localized to the urethra. Urinalysis in cystitis often shows bacteriuria and pyuria, while in urethritis, bacteriuria is usually absent (unless co-existing UTI), but pyuria may be present in first-void urine.

2. Reactive Arthritis:

   • Overlap: Urethritis can be a component of reactive arthritis.
   • Differentiation: Reactive arthritis is characterized by a triad of arthritis, conjunctivitis, and urethritis, typically occurring after a genitourinary or gastrointestinal infection. Arthritis is the predominant symptom, often affecting large joints, and is accompanied by conjunctivitis and sometimes mucocutaneous lesions. Urethritis in reactive arthritis is often milder.

3. Interstitial Cystitis/Bladder Pain Syndrome:

   • Overlap: Dysuria, urinary frequency, and pelvic pain can be present in both conditions.
   • Differentiation: Interstitial cystitis is a chronic condition characterized by bladder pain and urinary symptoms without evidence of infection. Urethritis is typically acute and associated with infection or irritation.

4. Prostatitis (in males):

   • Overlap: Dysuria, pelvic pain, and sometimes urethral discharge can occur in prostatitis.
   • Differentiation: Prostatitis often presents with perineal, pelvic, or lower back pain, ejaculatory pain, and systemic symptoms like fever and chills in acute bacterial prostatitis. Digital rectal exam reveals a tender and swollen prostate in acute prostatitis. Urethritis is more focused on urethral symptoms and discharge.

5. Epididymitis/Orchitis (in males):

   • Overlap: Testicular pain can occur in urethritis and epididymitis/orchitis.
   • Differentiation: Epididymitis/orchitis is characterized by testicular pain, swelling, and tenderness on palpation. Urethral symptoms may be present concurrently, but testicular findings are prominent.

6. Proctitis:

   • Overlap: Urethral symptoms can sometimes be associated with proctitis, especially in MSM.
   • Differentiation: Proctitis primarily involves rectal pain, discharge, bleeding, and tenesmus. Sexual history and anorectal examination are important to differentiate.

7. Urethral Trauma/Stricture:

   • Overlap: Dysuria and urethral discharge can occur.
   • Differentiation: History of urethral instrumentation, injury, or prior urethritis may suggest urethral stricture. Urethral discharge in stricture is less likely to be purulent. Urethroscopy and imaging may be needed for diagnosis.

8. Chemical Irritation:

   • Overlap: Urethral irritation and dysuria.
   • Differentiation: History of exposure to chemical irritants (soaps, spermicides, douches). Symptoms resolve upon removal of irritant.

9. Vaginitis/Cervicitis (in females):

   • Overlap: Dysuria, vaginal discharge, and pelvic discomfort.
   • Differentiation: Vaginitis and cervicitis primarily involve vaginal discharge, odor, itching, and cervical inflammation. Urethritis may coexist, but vaginal/cervical symptoms are more prominent. Pelvic examination helps differentiate.

10. Idiopathic Dysuria:

    • Definition: Dysuria without identifiable cause.
    • Diagnosis of Exclusion: Considered when all other causes are ruled out.

Diagnostic Approach for Differential Diagnosis:

• Detailed History: Symptom characteristics, sexual history, medical history, medication history.
• Physical Examination: Genitourinary and pelvic examination, including assessment for urethral discharge, tenderness, lesions, and other findings.
• Laboratory Tests: Urinalysis, urine culture, Gram stain of urethral discharge, NAATs for STIs, and other tests as clinically indicated to rule out specific conditions.

By systematically considering these differential diagnoses and employing appropriate clinical and laboratory evaluations, clinicians can accurately diagnose urethritis and distinguish it from other conditions with overlapping symptoms, ensuring targeted and effective patient care.

Prognosis of Urethritis

The prognosis for patients with urethritis is generally excellent, particularly when diagnosed and treated promptly and appropriately. Cure rates are high with recommended antibiotic regimens.

Factors Contributing to Favorable Prognosis:

• Effective Antibiotic Therapy: Current antibiotic guidelines provide effective treatments for the most common causes of urethritis (N gonorrhoeae, C trachomatis, M genitalium, T vaginalis).
• Adherence to Treatment: Patient compliance with prescribed antibiotic regimens is crucial for successful eradication of infection.
• Partner Treatment: Treating sexual partners simultaneously prevents reinfection and ongoing transmission.
• Self-Limited Nature of NGU: Nongonococcal urethritis, even if untreated, often resolves spontaneously in many cases, although treatment is still recommended to prevent complications and transmission.

Factors that Can Affect Prognosis:

• Treatment Delay: Delayed diagnosis and treatment can increase the risk of complications.
• Antibiotic Resistance: Increasing antibiotic resistance, particularly in N gonorrhoeae and M genitalium, can complicate treatment and potentially affect prognosis if initial therapy fails. Susceptibility testing and alternative regimens may be needed.
• Reinfection: Failure to treat sexual partners or continued high-risk sexual behavior can lead to reinfection and recurrent episodes of urethritis.
• Complications: Development of complications like pelvic inflammatory disease (PID) in women or epididymitis in men can prolong recovery and potentially impact long-term outcomes, such as fertility.
• Less Common Pathogens: Urethritis caused by less common or resistant organisms may require more complex management and monitoring.

Importance of Follow-up:

• Test of Cure: Recommended for N gonorrhoeae and T vaginalis infections, and for Chlamydia trachomatis in pregnant women and cases of suspected treatment failure. For M. genitalium, test of cure is increasingly recommended due to resistance concerns.
• Symptom Monitoring: Patients should be advised to return for follow-up if symptoms persist or recur after treatment.
• Partner Management: Ensure partners are treated and educated about STI prevention.

Long-Term Outcomes:

• Resolution of Symptoms: Most patients experience complete resolution of urethritis symptoms with appropriate treatment.
• Prevention of Complications: Early diagnosis and treatment significantly reduce the risk of complications associated with urethritis, such as PID, ectopic pregnancy, infertility, and epididymitis.
• STI Prevention: Effective management of urethritis, including partner treatment and patient education on safe sex practices, contributes to broader STI prevention efforts.

In conclusion, the prognosis for urethritis is generally very good with timely and appropriate management. Clinicians play a crucial role in ensuring accurate urethritis diagnosis, initiating effective treatment, and providing patient education to optimize outcomes and prevent further STI transmission.

Complications of Urethritis

While urethritis is often effectively treated, untreated or complicated cases can lead to various complications, particularly if the causative agent is not eradicated or if the infection ascends. Understanding these potential complications is important for comprehensive patient management and long-term health.

Complications in Males:

• Epididymitis: Infection can spread from the urethra to the epididymis, causing epididymitis, characterized by testicular pain and swelling.
• Prostatitis: Urethritis can lead to inflammation of the prostate gland (prostatitis), causing pelvic pain, urinary symptoms, and sexual dysfunction.
• Urethral Stricture: Chronic inflammation and scarring from recurrent or severe urethritis can result in urethral strictures, causing obstructive urinary symptoms.
• Periurethral Abscess: In rare cases, infection can lead to the formation of abscesses around the urethra.
• Infertility: Untreated urethritis, particularly due to Chlamydia trachomatis and Neisseria gonorrhoeae, has been linked to male infertility due to impaired sperm parameters and sperm DNA damage.
• Reactive Arthritis: Urethritis, especially Chlamydia-related, can trigger reactive arthritis, a systemic inflammatory condition affecting joints, eyes, and urethra.

Complications in Females:

• Pelvic Inflammatory Disease (PID): Ascending infection from the urethra and cervix to the uterus, fallopian tubes, and ovaries can cause PID, a serious condition leading to chronic pelvic pain, ectopic pregnancy, and infertility. PID is a major complication of untreated Chlamydia and gonorrhea infections in women.
• Ectopic Pregnancy: PID-related damage to fallopian tubes increases the risk of ectopic pregnancy, a life-threatening condition where a fertilized egg implants outside the uterus.
• Infertility: PID is a leading cause of tubal factor infertility in women.
• Chronic Pelvic Pain: PID can result in chronic pelvic pain and discomfort.
• Fitz-Hugh-Curtis Syndrome: Perihepatitis (inflammation of the liver capsule) can occur as a complication of PID, particularly from Chlamydia or gonorrhea.

Complications in Neonates (from maternal urethritis during pregnancy):

• Conjunctivitis (Ophthalmia Neonatorum): Infants born to mothers with untreated gonorrhea or chlamydia can develop severe eye infections (conjunctivitis) during vaginal delivery. Routine antibiotic eye prophylaxis for newborns has significantly reduced this complication.
• Pneumonia: Chlamydia trachomatis can cause pneumonia in newborns.

Other Potential Complications:

• Disseminated Gonococcal Infection (DGI): In rare cases, gonorrhea can disseminate through the bloodstream, leading to systemic infection affecting skin, joints, and heart valves.
• Lymphogranuloma Venereum (LGV): A more invasive infection caused by specific serovars of Chlamydia trachomatis, LGV can cause lymphadenopathy, proctocolitis, and systemic symptoms.

Prevention of Complications:

• Early Diagnosis and Treatment: Prompt urethritis diagnosis and appropriate antibiotic therapy are essential to prevent complications.
• Partner Treatment: Treating sexual partners reduces the risk of reinfection and onward transmission.
• STI Prevention: Practicing safe sex, including consistent condom use, reduces the risk of acquiring STIs and subsequent urethritis and its complications.
• Screening: Routine STI screening for at-risk populations helps identify and treat infections early, before complications develop.

By recognizing the potential complications of urethritis, clinicians can emphasize the importance of early urethritis diagnosis, adherence to treatment, and preventive measures to minimize morbidity and long-term sequelae for patients.

Deterrence and Patient Education for Urethritis

Deterrence and patient education are crucial components of urethritis management, focusing on preventing new infections and reducing the spread of existing ones. Effective patient education empowers individuals to make informed decisions about their sexual health and take proactive steps to protect themselves and their partners.

Key Aspects of Deterrence and Patient Education:

1. Safe Sexual Practices:

   • Condom Use: Emphasize the importance of consistent and correct condom use during vaginal, anal, and oral sex to reduce the risk of STI transmission, including pathogens causing urethritis.
   • Limiting Sexual Partners: Educate patients that reducing the number of sexual partners decreases the risk of STI exposure.
   • Open Communication with Partners: Encourage open and honest communication with sexual partners about STI status and sexual history.

2. Partner Notification and Treatment:

   • Importance of Partner Treatment: Explain to patients diagnosed with urethritis the necessity of informing their recent sexual partners (typically within the last 60 days) about their diagnosis and encouraging them to seek testing and treatment.
   • Preventing Reinfection: Stress that partner treatment is essential to prevent reinfection and ongoing transmission.
   • Asymptomatic Infections: Educate patients that partners may be asymptomatic but still carry and transmit the infection.

3. Abstinence During Treatment:

   • Avoid Intercourse: Advise patients to abstain from sexual intercourse until they and their partners have completed treatment and are symptom-free (typically for 7 days after starting treatment and after symptoms resolve).

4. Risk Factor Awareness:

   • Identify Risk Factors: Educate patients about risk factors for urethritis and STIs, such as young age, multiple partners, unprotected sex, history of STIs, MSM status, and commercial sex work.
   • Risk Reduction Strategies: Discuss strategies to reduce risk based on individual circumstances.

5. Importance of Testing and Screening:

   • Regular STI Screening: Recommend regular STI screening for sexually active individuals, especially those with risk factors.
   • Early Detection: Emphasize that early urethritis diagnosis and treatment are crucial for preventing complications and further transmission.

6. Recurrence and Persistent Symptoms:

   • Possibility of Recurrence: Inform patients that urethritis can recur, especially if partners are not treated or if high-risk behaviors continue.
   • Persistent Symptoms: Advise patients to return for follow-up if symptoms persist or recur after treatment to evaluate for treatment failure, reinfection, or less common pathogens.

7. Specific STI Information:

   • Pathogen-Specific Education: Provide information about the specific pathogen causing urethritis (e.g., gonorrhea, chlamydia, M genitalium, T vaginalis), its transmission, symptoms, and potential complications.
   • Antibiotic Resistance: In the context of gonorrhea and M genitalium, briefly explain the issue of antibiotic resistance and the importance of completing prescribed treatment and follow-up testing.

8. Resources and Support:

   • Provide Resources: Offer information about local STI clinics, testing centers, and online resources for sexual health information.
   • Address Concerns: Create a comfortable and non-judgmental environment for patients to ask questions and express concerns about their sexual health.

Tailoring Education:

• Individualized Approach: Tailor patient education to individual risk factors, sexual practices, and understanding level.
• Culturally Sensitive Communication: Use culturally sensitive and respectful language when discussing sexual health topics.
• Reinforce Key Messages: Repeat key messages about safe sex, partner treatment, and follow-up to ensure patient understanding and adherence.

Effective deterrence and patient education are integral to managing urethritis and reducing the broader burden of STIs in the community. By empowering patients with knowledge and promoting responsible sexual health practices, clinicians can contribute significantly to public health efforts.

Pearls and Other Key Considerations in Urethritis Diagnosis and Management

• Most Common Pathogens: The primary causative organisms of urethritis are Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium.
• Resistant/Recurrent Urethritis: Mycoplasma genitalium and Trichomonas vaginalis are frequently implicated in persistent or recurrent urethritis cases.
• Typical Presentation: Dysuria and urethral discharge are the most common presenting symptoms of urethritis.
• Diagnostic Criteria: Urethritis diagnosis is based on microscopic examination of urethral discharge showing ≥2 WBCs, or first-void urine with ≥10 WBCs, or mucopurulent/purulent discharge.
• Initial Empiric Therapy: If gonococcal urethritis cannot be ruled out, initial treatment should include ceftriaxone and doxycycline to cover both gonococcal and nongonococcal infections.
• STI Screening: Patients suspected of having an STI-related urethritis should also be tested for syphilis and HIV.
• NAAT Testing: Nucleic acid amplification tests (NAATs) are highly sensitive for detecting C trachomatis, N gonorrhoeae, T vaginalis, and M genitalium (if available).
• Partner Management: Instruct patients to abstain from sex for 7 days after starting treatment and to ensure that all sexual partners are tested and treated.
• Consider Less Common Causes: In persistent or atypical cases, consider less common etiologies like adenovirus, Haemophilus influenzae, Candida, or non-infectious causes.
• Antibiotic Resistance: Be aware of increasing antibiotic resistance in N gonorrhoeae and M genitalium and consider local resistance patterns when choosing antibiotics.
• Patient Comfort and Communication: Create a comfortable and non-judgmental environment to facilitate open communication with patients about their sexual history and symptoms, which is crucial for accurate urethritis diagnosis and management.
• Interprofessional Collaboration: Effective management of urethritis benefits from an interprofessional healthcare team approach involving physicians, nurses, pharmacists, and social workers to optimize patient care, medication adherence, and public health reporting.

Enhancing Healthcare Team Outcomes in Urethritis Management

Optimizing outcomes for patients with urethritis and contributing to broader STI control requires a collaborative and interprofessional healthcare team approach. Effective teamwork enhances urethritis diagnosis, treatment adherence, patient education, and public health reporting.

Key Strategies for Enhancing Healthcare Team Outcomes:

1. Interprofessional Collaboration:

   • Team-Based Care: Involve physicians, nurses, pharmacists, medical assistants, and social workers in patient care.
   • Clear Roles and Responsibilities: Define roles for each team member to ensure coordinated and efficient care delivery.
   • Regular Communication: Establish channels for regular communication among team members to share patient information, discuss treatment plans, and address any concerns.

2. Physician Role:

   • Accurate Diagnosis: Conduct thorough history and physical exams, order appropriate diagnostic tests for accurate urethritis diagnosis.
   • Evidence-Based Treatment: Prescribe guideline-recommended antibiotic regimens, considering patient factors and antibiotic resistance patterns.
   • Patient Education: Provide comprehensive patient education on urethritis, STIs, safe sex practices, partner treatment, and follow-up.
   • Referral and Consultation: Consult infectious disease specialists or other specialists when needed for complex cases or treatment failures.

3. Nursing Role:

   • Patient Assessment and Monitoring: Assist with patient assessment, monitor symptoms, and track treatment progress.
   • Medication Administration and Education: Administer medications (e.g., IM ceftriaxone), educate patients on medication adherence, side effects, and importance of completing treatment.
   • Counseling and Support: Provide counseling on STI prevention, safe sex practices, partner notification, and address patient questions and concerns.
   • Follow-up and Coordination: Schedule follow-up appointments, ensure test-of-cure is performed when indicated, and coordinate care with other team members.

4. Pharmacist Role:

   • Medication Management: Verify antibiotic prescriptions for appropriateness, dosage, and drug interactions.
   • Antibiotic Stewardship: Promote judicious antibiotic use and adherence to guidelines to combat antibiotic resistance.
   • Patient Counseling: Counsel patients on medication administration, potential side effects, and importance of completing the full course of antibiotics.
   • Accessibility and Affordability: Address medication access and affordability issues for patients.

5. Medical Assistant Role:

   • Patient Intake and Preparation: Obtain patient history, vital signs, and prepare patients for examination.
   • Specimen Collection: Assist with collecting urethral swabs, urine samples, and other specimens for diagnostic testing.
   • Patient Communication and Scheduling: Communicate appointment reminders, test results, and schedule follow-up visits.

6. Social Worker Role:

   • Resource Navigation: Assist patients in accessing community resources, such as STI clinics, support groups, and financial assistance programs.
   • Addressing Barriers to Care: Identify and address social determinants of health that may hinder access to care or treatment adherence (e.g., transportation, housing, insurance).
   • Confidentiality and Support: Provide a confidential and supportive environment for patients to discuss sensitive issues.

7. Public Health Reporting:

   • Mandatory Reporting: Ensure timely and accurate reporting of reportable STIs (e.g., gonorrhea, chlamydia, syphilis) to public health agencies, as legally required.
   • Data Collection and Surveillance: Contribute to public health surveillance efforts to monitor STI trends and inform prevention strategies.

Enhancing Communication and Trust:

• Doctor-Patient Relationship: Build a strong doctor-patient relationship based on trust, respect, and open communication.
• Non-Judgmental Approach: Create a non-judgmental and supportive atmosphere where patients feel comfortable discussing sexual health concerns.
• Confidentiality: Maintain strict patient confidentiality to encourage honest disclosure of sensitive information.

By implementing these strategies and fostering a collaborative interprofessional team approach, healthcare providers can significantly improve the quality of care for patients with urethritis, enhance treatment outcomes, and contribute to the overall effort of STI prevention and control in the community.

Review Questions

(Note: Review questions from the original article are not directly relevant to rewriting and SEO optimization task, and hence are omitted as per instructions. Focus is on creating improved content based on the source text.)

References

(Note: References from the original article are preserved to maintain the factual accuracy and provide source credibility. They are listed below in markdown format as requested.)

1.Burstein GR, Zenilman JM. Nongonococcal urethritis–a new paradigm. Clin Infect Dis. 1999 Jan;28 Suppl 1:S66-73. [PubMed: 10028111]
2.Ito S, Hanaoka N, Shimuta K, Seike K, Tsuchiya T, Yasuda M, Yokoi S, Nakano M, Ohnishi M, Deguchi T. Male non-gonococcal urethritis: From microbiological etiologies to demographic and clinical features. Int J Urol. 2016 Apr;23(4):325-31. [PubMed: 26845624]
3.Totten PA, Schwartz MA, Sjöström KE, Kenny GE, Handsfield HH, Weiss JB, Whittington WL. Association of Mycoplasma genitalium with nongonococcal urethritis in heterosexual men. J Infect Dis. 2001 Jan 15;183(2):269-276. [PubMed: 11120932]
4.Garcia MR, Leslie SW, Wray AA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 20, 2024. Sexually Transmitted Infections. [PubMed: 32809643]
5.Mohseni M, Sung S, Takov V. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Chlamydia. [PubMed: 30725971]
6.Gunn RA, O’Brien CJ, Lee MA, Gilchick RA. Gonorrhea screening among men who have sex with men: value of multiple anatomic site testing, San Diego, California, 1997-2003. Sex Transm Dis. 2008 Oct;35(10):845-8. [PubMed: 18607315]
7.Lee YS, Lee KS. Chlamydia and male lower urinary tract diseases. Korean J Urol. 2013 Feb;54(2):73-7. [PMC free article: PMC3580308] [PubMed: 23550267]
8.Moazenchi M, Totonchi M, Salman Yazdi R, Hratian K, Mohseni Meybodi MA, Ahmadi Panah M, Chehrazi M, Mohseni Meybodi A. The impact of Chlamydia trachomatis infection on sperm parameters and male fertility: A comprehensive study. Int J STD AIDS. 2018 Apr;29(5):466-473. [PubMed: 29065772]
9.Ahmadi K, Moosavian M, Mardaneh J, Pouresmaeil O, Afzali M. Prevalence of Chlamydia trachomatis, Ureaplasma parvum and Mycoplasma genitalium in Infertile Couples and the Effect on Semen Parameters. Ethiop J Health Sci. 2023 Jan;33(1):133-142. [PMC free article: PMC9987280] [PubMed: 36890937]
10.Khalafalla K, El Ansari W, Sengupta P, Majzoub A, Elbardisi H, Canguven O, El-Ansari K, Arafa M. Are sexually transmitted infections associated with male infertility? A systematic review and in-depth evaluation of the evidence and mechanisms of action of 11 pathogens. Arab J Urol. 2023;21(4):216-232. [PMC free article: PMC10763591] [PubMed: 38178949]
11.Springer C, Salen P. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 17, 2023. Gonorrhea. [PubMed: 32644329]
12.Bradshaw CS, Denham IM, Fairley CK. Characteristics of adenovirus associated urethritis. Sex Transm Infect. 2002 Dec;78(6):445-7. [PMC free article: PMC1758335] [PubMed: 12473808]
13.Bedük Y, Manalp M. [Detection of candidiasis in non-gonococcal urethritis resistant to therapy]. Mikrobiyol Bul. 1986 Jul;20(3):190-5. [PubMed: 3561282]
14.R AN, Rafiq NB. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 29, 2023. Candidiasis. [PubMed: 32809459]
15.Galan-Sanchez F, Aznar-Marin P, Marin-Casanova P, Garcia-Martos P, Rodriguez-Iglesias M. Urethritis due to Corynebacterium glucuronolyticum. J Infect Chemother. 2011 Oct;17(5):720-1. [PubMed: 21437677]
16.Ruiz-Pino M, Foronda-García-Hidalgo C, Alarcón-Blanco P, Gutiérrez-Fernández J. Male genitourinary infections by Corynebacterium glucuronolyticum. A review and clinical experience. Rev Esp Quimioter. 2019 Oct;32(5):479-484. [PMC free article: PMC6790891] [PubMed: 31515978]
17.Khattak ZE, Anjum F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Apr 27, 2023. Haemophilus influenzae Infection. [PubMed: 32965847]
18.Saleh D, Yarrarapu SNS, Sharma S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 28, 2023. Herpes Simplex Type 1. [PubMed: 29489260]
19.Mathew Jr J, Sapra A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 13, 2024. Herpes Simplex Type 2. [PubMed: 32119314]
20.Nguyen N, Ashong D. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 27, 2024. Meningococcal Disease (Neisseria meningitidis Infection) [PubMed: 31751039]
21.Tudor ME, Al Aboud AM, Leslie SW, Gossman W. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 17, 2024. Syphilis. [PubMed: 30521201]
22.Sethi S, Sharma N, Singh C, Chaudhry H, Dadwal R, Malhotra S, Gupta V. A retrospective analysis of sexually transmitted infections among males presenting to a tertiary care hospital of India. Indian J Sex Transm Dis AIDS. 2022 Jul-Dec;43(2):170-173. [PMC free article: PMC9891002] [PubMed: 36743091]
23.Workowski KA, Bolan GA., Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 05;64(RR-03):1-137. [PMC free article: PMC5885289] [PubMed: 26042815]
24.Lanao AE, Chakraborty RK, Pearson-Shaver AL. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 7, 2023. Mycoplasma Infections. [PubMed: 30725612]
25.Bachmann LH, Manhart LE, Martin DH, Seña AC, Dimitrakoff J, Jensen JS, Gaydos CA. Advances in the Understanding and Treatment of Male Urethritis. Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S763-9. [PubMed: 26602615]
26.Flores SA, Hall CA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 31, 2022. Atrophic Vaginitis. [PubMed: 33232011]
27.Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, Su J, Xu F, Weinstock H. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013 Mar;40(3):187-93. [PubMed: 23403598]
28.Berntsson M, Tunbäck P. Clinical and microscopic signs of cervicitis and urethritis: correlation with Chlamydia trachomatis infection in female STI patients. Acta Derm Venereol. 2013 Mar 27;93(2):230-3. [PubMed: 23460336]
29.Ceovic R, Gulin SJ. Lymphogranuloma venereum: diagnostic and treatment challenges. Infect Drug Resist. 2015;8:39-47. [PMC free article: PMC4381887] [PubMed: 25870512]
30.Schumann JA, Plasner S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 12, 2023. Trichomoniasis. [PubMed: 30521247]
31.Bradshaw CS, Tabrizi SN, Read TR, Garland SM, Hopkins CA, Moss LM, Fairley CK. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis. 2006 Feb 01;193(3):336-45. [PubMed: 16388480]
32.Hobbs MM, Kazembe P, Reed AW, Miller WC, Nkata E, Zimba D, Daly CC, Chakraborty H, Cohen MS, Hoffman I. Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis. 1999 Aug;26(7):381-7. [PubMed: 10458630]
33.Dalby J, Stoner BP. Sexually Transmitted Infections: Updates From the 2021 CDC Guidelines. Am Fam Physician. 2022 May 01;105(5):514-520. [PubMed: 35559639]
34.Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. [PMC free article: PMC8344968] [PubMed: 34292926]
35.Workowski KA, Berman SM. Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment Guidelines. Clin Infect Dis. 2011 Dec;53 Suppl 3:S59-63. [PubMed: 22080270]
36.Elwell C, Mirrashidi K, Engel J. Chlamydia cell biology and pathogenesis. Nat Rev Microbiol. 2016 Jun;14(6):385-400. [PMC free article: PMC4886739] [PubMed: 27108705]
37.Shahmanesh M, Moi H, Lassau F, Janier M., IUSTI/WHO. 2009 European guideline on the management of male non-gonococcal urethritis. Int J STD AIDS. 2009 Jul;20(7):458-64. [PubMed: 19541886]
38.Meštrović T. A microbial game of whack-a-mole: clinical case series of the urethral uncloaking phenomenon caused by Corynebacterium glucuronolyticum in men treated for Chlamydia trachomatis urethritis. Infection. 2019 Feb;47(1):121-124. [PubMed: 30168068]
39.Meštrović T, Neuberg M, Sviben M, Ribić R, Drenjančević D, Škrlec I, Talapko J, Kozina G, Profozić Z. Corynebacterium glucuronolyticum in men with and without urethritis syndrome: An underrecognized pathogen or a bona fide commensal? Infect Dis Now. 2022 Nov;52(8):441-446. [PubMed: 36030041]
40.Henkel R. Long-term consequences of sexually transmitted infections on men’s sexual function: A systematic review. Arab J Urol. 2021;19(3):411-418. [PMC free article: PMC8451632] [PubMed: 34552793]
41.Rietmeijer CA, Mettenbrink CJ. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis. 2012 Jan;39(1):18-20. [PubMed: 22183839]
42.Rietmeijer CA, Mungati M, Machiha A, Mugurungi O, Kupara V, Rodgers L, Kilmarx PH, Roloff AH, Gonese E, Tippett-Barr BA, Shambira G, Lewis DA, Handsfield HH, Tshimanga M. The Etiology of Male Urethral Discharge in Zimbabwe: Results from the Zimbabwe STI Etiology Study. Sex Transm Dis. 2018 Jan;45(1):56-60. [PMC free article: PMC10719555] [PubMed: 29240635]
43.Sarier M, Sepin N, Duman I, Demir M, Hizel A, Göktaş Ş, Emek M, Kukul E, Soylu A. Microscopy of Gram-stained urethral smear in the diagnosis of urethritis: Which threshold value should be selected? Andrologia. 2018 Dec;50(10):e13143. [PubMed: 30238498]
44.Sarier M, Kukul E. Classification of non-gonococcal urethritis: a review. Int Urol Nephrol. 2019 Jun;51(6):901-907. [PubMed: 30953260]
45.Tripathi N, Sapra A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 14, 2023. Gram Staining. [PubMed: 32965827]
46.Kingston MA, Bansal D, Carlin EM. ‘Shelf life’ of Trichomonas vaginalis. Int J STD AIDS. 2003 Jan;14(1):28-9. [PubMed: 12590789]
47.Muzny CA, Blackburn RJ, Sinsky RJ, Austin EL, Schwebke JR. Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic. Clin Infect Dis. 2014 Sep 15;59(6):834-41. [PubMed: 24928292]
48.Schwebke JR, Hobbs MM, Taylor SN, Sena AC, Catania MG, Weinbaum BS, Johnson AD, Getman DK, Gaydos CA. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol. 2011 Dec;49(12):4106-11. [PMC free article: PMC3232944] [PubMed: 21940475]
49.Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Miller WC, Hobbs MM. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis. 2007 Jul 15;45(2):194-8. [PubMed: 17578778]
50.Taylor SN, DiCarlo RP, Martin DH. Comparison of methylene blue/gentian violet stain to Gram’s stain for the rapid diagnosis of gonococcal urethritis in men. Sex Transm Dis. 2011 Nov;38(11):995-6. [PubMed: 21992973]
51.Taylor-Robinson D, Gilroy CB, Thomas BJ, Hay PE. Mycoplasma genitalium in chronic non-gonococcal urethritis. Int J STD AIDS. 2004 Jan;15(1):21-5. [PubMed: 14769166]
52.Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA. Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. Am J Public Health. 2007 Jun;97(6):1118-25. [PMC free article: PMC1874220] [PubMed: 17463380]
53.Edouard S, Tissot-Dupont H, Dubourg G, Bernard A, Fournier PE, Ravaux I, Stein A, Raoult D. Mycoplasma genitalium, an agent of reemerging sexually transmitted infections. APMIS. 2017 Oct;125(10):916-920. [PubMed: 28762558]
54.Bradshaw CS, Fairley CK, Lister NA, Chen SJ, Garland SM, Tabrizi SN. Mycoplasma genitalium in men who have sex with men at male-only saunas. Sex Transm Infect. 2009 Oct;85(6):432-5. [PubMed: 19254902]
55.Mullis CE, Marlow KA, Maity A, Fazzari M, Zingman BS, Keller MJ, Meyerowitz EA. Clinical Presentations and Treatment Outcomes of Mycoplasma genitalium Infections at a Large New York City Health Care System. Sex Transm Dis. 2024 Mar 01;51(3):199-205. [PMC free article: PMC10922512] [PubMed: 38100794]
56.Mena L, Wang X, Mroczkowski TF, Martin DH. Mycoplasma genitalium infections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis. 2002 Nov 15;35(10):1167-73. [PubMed: 12410476]
57.Magdaleno-Tapial J, Valenzuela-Oñate C, Giacaman-von der Weth MM, Ferrer-Guillén B, Martínez-Domenech Á, García-Legaz Martínez M, Ortiz-Salvador JM, Subiabre-Ferrer D, Hernández-Bel P. Haemophilus Species Isolated in Urethral Exudates as a Possible Causative Agent in Acute Urethritis: A Study of 38 Cases. Actas Dermosifiliogr (Engl Ed). 2019 Jan-Feb;110(1):38-42. [PubMed: 30390917]
58.Ben Lahlou Y, Malihy Z, Benaissa M, Chadli M, Elouennass M. Haemophilus influenzae Urethritis: A Localization to Consider. Cureus. 2023 Jul;15(7):e42601. [PMC free article: PMC10460499] [PubMed: 37641768]
59.Ito S, Hatazaki K, Shimuta K, Kondo H, Mizutani K, Yasuda M, Nakane K, Tsuchiya T, Yokoi S, Nakano M, Ohinishi M, Deguchi T. Haemophilus influenzae Isolated From Men With Acute Urethritis: Its Pathogenic Roles, Responses to Antimicrobial Chemotherapies, and Antimicrobial Susceptibilities. Sex Transm Dis. 2017 Apr;44(4):205-210. [PubMed: 28282645]
60.Horie K, Ito S, Hatazaki K, Yasuda M, Nakano M, Kawakami K, Fujita Y, Ito M, Ezaki T, Deguchi T. ‘Haemophilus quentini’ in the urethra of men complaining of urethritis symptoms. J Infect Chemother. 2018 Jan;24(1):71-74. [PubMed: 28889986]
61.Cheeti A, Chakraborty RK, Ramphul K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 2, 2023. Reactive Arthritis. [PubMed: 29763006]
62.Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014 Apr-May;13(4-5):546-9. [PubMed: 24418301]
63.Quilter LAS, St Cyr SB, Barbee LA. The Management of Gonorrhea in the Era of Emerging Antimicrobial Resistance: What Primary Care Clinicians Should Know. Med Clin North Am. 2024 Mar;108(2):279-296. [PMC free article: PMC11150008] [PubMed: 38331480]
64.Kirkcaldy RD, Weinstock HS, Moore PC, Philip SS, Wiesenfeld HC, Papp JR, Kerndt PR, Johnson S, Ghanem KG, Hook EW. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014 Oct 15;59(8):1083-91. [PMC free article: PMC4271098] [PubMed: 25031289]
65.Barbee LA, Soge OO, Ocbamichael N, LeClair A, Golden MR. Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2020 Dec 16;65(1) [PMC free article: PMC7927842] [PubMed: 33077658]
66.Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis. 1995 Apr;20 Suppl 1:S47-65. [PubMed: 7795109]
67.Singh V, Bala M, Bhargava A, Kakran M, Bhatnagar R. In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era. PLoS One. 2018;13(3):e0193678. [PMC free article: PMC5839552] [PubMed: 29509792]
68.Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill. 2011 Apr 07;16(14) [PubMed: 21492528]
69.Frølund M, Lidbrink P, Wikström A, Cowan S, Ahrens P, Jensen JS. Urethritis-associated Pathogens in Urine from Men with Non-gonococcal Urethritis: A Case-control Study. Acta Derm Venereol. 2016 Jun 15;96(5):689-94. [PubMed: 26658669]
70.Rane VS, Fairley CK, Weerakoon A, Read TH, Fehler G, Chen MY, Bradshaw CS. Characteristics of acute nongonococcal urethritis in men differ by sexual preference. J Clin Microbiol. 2014 Aug;52(8):2971-6. [PMC free article: PMC4136159] [PubMed: 24899041]
71.Kong FY, Tabrizi SN, Law M, Vodstrcil LA, Chen M, Fairley CK, Guy R, Bradshaw C, Hocking JS. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014 Jul 15;59(2):193-205. [PubMed: 24729507]
72.Páez-Canro C, Alzate JP, González LM, Rubio-Romero JA, Lethaby A, Gaitán HG. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev. 2019 Jan 25;1(1):CD010871. [PMC free article: PMC6353232] [PubMed: 30682211]
73.Bachmann LH, Kirkcaldy RD, Geisler WM, Wiesenfeld HC, Manhart LE, Taylor SN, Seña AC, McNeil CJ, Newman L, Myler N, Fuchs R, Bowden KE., MAGNUM Laboratory Working Group. Prevalence of Mycoplasma genitalium Infection, Antimicrobial Resistance Mutations, and Symptom Resolution Following Treatment of Urethritis. Clin Infect Dis. 2020 Dec 17;71(10):e624-e632. [PMC free article: PMC7744987] [PubMed: 32185385]
74.Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014 Mar;58(5):631-7. [PMC free article: PMC3922211] [PubMed: 24280088]
75.Li Y, Su X, Le W, Li S, Yang Z, Chaisson C, Madico G, Gong X, Reed GW, Wang B, Rice PA. Mycoplasma genitalium in Symptomatic Male Urethritis: Macrolide Use Is Associated With Increased Resistance. Clin Infect Dis. 2020 Feb 14;70(5):805-810. [PMC free article: PMC7390511] [PubMed: 30972419]
76.McIver R, Jalocon D, McNulty A, Jeoffreys NJ, Chen SC, Power M, Couldwell DL. Men Who Have Sex With Men With Mycoplasma genitalium-Positive Nongonococcal Urethritis Are More Likely to Have Macrolide-Resistant Strains Than Men With Only Female Partners: A Prospective Study. Sex Transm Dis. 2019 Aug;46(8):513-517. [PubMed: 31295218]
77.Kissinger PJ, White S, Manhart LE, Schwebke J, Taylor SN, Mena L, Khosropour CM, Wilcox L, Schmidt N, Martin DH. Azithromycin Treatment Failure for Chlamydia trachomatis Among Heterosexual Men With Nongonococcal Urethritis. Sex Transm Dis. 2016 Oct;43(10):599-602. [PMC free article: PMC5033507] [PubMed: 27631353]
78.Schwebke JR, Rompalo A, Taylor S, Seña AC, Martin DH, Lopez LM, Lensing S, Lee JY. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens–a randomized clinical trial. Clin Infect Dis. 2011 Jan 15;52(2):163-70. [PMC free article: PMC3106252] [PubMed: 21288838]
79.Read TRH, Fairley CK, Murray GL, Jensen JS, Danielewski J, Worthington K, Doyle M, Mokany E, Tan L, Chow EPF, Garland SM, Bradshaw CS. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. Clin Infect Dis. 2019 Feb 01;68(4):554-560. [PMC free article: PMC6355821] [PubMed: 29873691]
80.Li Y, Le WJ, Li S, Cao YP, Su XH. Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection. Int J STD AIDS. 2017 Oct;28(11):1106-1114. [PubMed: 28118803]
81.Read TRH, Jensen JS, Fairley CK, Grant M, Danielewski JA, Su J, Murray GL, Chow EPF, Worthington K, Garland SM, Tabrizi SN, Bradshaw CS. Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection. Emerg Infect Dis. 2018 Feb;24(2):328-335. [PMC free article: PMC5782881] [PubMed: 29350154]
82.Chua TP, Bodiyabadu K, Machalek DA, Garland SM, Bradshaw CS, Plummer EL, Danielewski J, Vodstrcil LA, Doyle ML, Murray GL. Prevalence of Mycoplasma genitalium fluoroquinolone-resistance markers, and dual-class-resistance markers, in asymptomatic men who have sex with men. J Med Microbiol. 2021 Sep;70(9) [PMC free article: PMC8697509] [PubMed: 34590993]
83.Kissinger PJ, Gaydos CA, Seña AC, Scott McClelland R, Soper D, Secor WE, Legendre D, Workowski KA, Muzny CA. Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis. 2022 Apr 13;74(Suppl_2):S152-S161. [PMC free article: PMC9006969] [PubMed: 35416973]
84.National guideline for the management of Trichomonas vaginalis. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect. 1999 Aug;75 Suppl 1:S21-3. [PubMed: 10616377]
85.Mehta P, Leslie SW, Reddivari AKR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 12, 2023. Dysuria. [PubMed: 31751108]
86.Scholes D, Satterwhite CL, Yu O, Fine D, Weinstock H, Berman S. Long-term trends in Chlamydia trachomatis infections and related outcomes in a U.S. managed care population. Sex Transm Dis. 2012 Feb;39(2):81-8. [PubMed: 22249294]
87.Jouglet M, Wuillaume I, Buchs C, Reix P, Schweitzer C, Coutier L. Neonatal low respiratory tract chlamydia trachomatis infection: Diagnostic and treatment management. Respir Med Case Rep. 2019;28:100852. [PMC free article: PMC6562265] [PubMed: 31211044]
88.Numazaki K, Wainberg MA, McDonald J. Chlamydia trachomatis infections in infants. CMAJ. 1989 Mar 15;140(6):615-22. [PMC free article: PMC1268751] [PubMed: 2645987]
89.Rawla P, Thandra KC, Limaiem F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 31, 2023. Lymphogranuloma Venereum. [PubMed: 30726047]
90.Frølund M, Wikström A, Lidbrink P, Abu Al-Soud W, Larsen N, Harder CB, Sørensen SJ, Jensen JS, Ahrens P. The bacterial microbiota in first-void urine from men with and without idiopathic urethritis. PLoS One. 2018;13(7):e0201380. [PMC free article: PMC6063444] [PubMed: 30052651]

---

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of medical conditions.